Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study

Alberto Floris1,2†, Matteo Piga1,2*, Riccardo Laconi1,2, Gerard Espinosa3, Giuseppe Lopalco4, Luisa Serpa Pinto5, Nikolaos Kougkas6,7, Jurgen Sota8, Andrea Lo Monaco9, Marcello Govoni3, Luca Cantarini8, George Bertsias6, João Correia5, Florenzo Iannone4, Ricard Cervera3, Carlos Vasconcelos10, Alessandro Mathieu1 and Alberto Cauli1,2

Abstract

Background: This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behçet’s syndrome (BS) over 2 years of follow-up.

Methods: Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase ≥ 1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains.

Results: During follow-up, 36 out of 189 (19.0%) patients had an increase ≥ 1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p < 0.001). The incidence rate of damage accrual was stable over time, regardless of the disease duration. Out of 61 new BODI items, 25 (41.0%) were considered related to glucocorticoid (GC) use. In multivariate analysis, duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07–1.23; p < 0.001) and occurrence of ≥ 1 disease relapse (OR 3.15, 95% CI 1.09–9.12; p = 0.038) were identified as predictors of damage accrual, whereas the use of immunosuppressants showed a protective effect (OR 0.20, 95% CI 0.08–0.54, p < 0.001). Damage accrual was independently associated with the impairment of different physical domains and, to a greater extent, in emotional domains of the SF-36 questionnaire. Female sex, higher disease activity, and fibromyalgia were also significantly associated with impairment in HR-QoL.

Conclusion: In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual.

Introduction

Behçet’s syndrome (BS) is a multisystem inflammatory disease characterized by a strong genetic background and a relapsing-remitting course [1, 2]. In patients affected with BS, both disease activity and treatment...
may lead to the accrual of organ damage, defined as any irreversible anatomic or functional alteration potentially resulting in impaired quality of life and increased morbidity and mortality [2, 3].

According to the European Alliance of Associations for Rheumatology (EULAR) recommendations, preventing the accrual of organ damage is a primary goal in treating BS patients [4]. However, although this is one of the most widely accepted and shared general principles, there is still insufficient knowledge about the incidence, trajectory, qualitative features, and risk factors of damage accrual in BS. Moreover, no direct data on how damage affects other short- and long-term outcomes, such as quality of life (QoL), are currently available.

In this context, the recent development of Behçet's syndrome Overall Damage Index (BODI), the first damage assessment tool specifically designed for BS, may favour significant advances in the knowledge about the characteristics and outcomes of damage accrual, supporting the design of effective preventive strategies [3].

In a preliminary cross-sectional study, male sex, longer disease duration, major organ involvement, and lack of use of TNF inhibitors were significantly associated with the presence of damage evaluated using the BODI [3]. Conversely, no significant association was recorded between the extent of damage and the impairment of health-related quality of life (HR-QoL) [3]. However, the cross-sectional nature of this study prevented assessing the temporal link between damage accrual and impairment of HR-QoL. Indeed, a longitudinal study design is needed to evaluate the incidence of organ damage accrual, predictive factors, and associated short- and long-term outcomes [5].

The present study reports on the 2-year follow-up extension of the BODI validation cohort, aiming to investigate the trajectory of damage accrual, associated factors, and impact on HR-QoL in patients with BS.

**Methods**

**Study design and outcomes**

The present study included and followed up for 2 years the patients enrolled in the BODI validation study, a multicenter cohort of BS patients recruited according to the following inclusion criteria: (a) diagnosis of BS fulfilling the International Study Group (ISG) criteria [6] or the International Criteria for Behçet's Disease (ICBD) [7], (b) disease duration ≥12 months, (c) age at enrollment ≥18 years and (d) ability to provide informed consent.

Active and cumulative clinical manifestations, previous and ongoing medications, and overall disease activity assessed by the Behçet's Disease Current Activity Form (BDCAF) [8], the Physician Global Assessment (PGA) [9], and the Patient Global Assessment (PtGA) [9] were recorded during follow-up. Furthermore, disease relapses, defined by any treatment escalation due to disease activity during follow-up, were recorded. The HR-QoL and the extent and type of organ damage were recorded at baseline and 2-year follow-up visits.

The HR-QoL was assessed by the SF-36 questionnaire, which consists of a multipurpose, generic (no disease-specific) short-form health survey with only 36 questions. It yields an eight-scale profile of scores as well as physical and mental health summary measures (higher scores correspond to higher HR-QoL) [10]. In this study, all eight domains of the SF-36 questionnaire were assessed: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), mental health (MH), vitality (VT), social functioning (SF), and role emotional (RE). The results were then summarized in the Physical Component Summary (PCS), measuring the physical domains of QoL (PF, RP, BP, GH), and in the Mental Component Summary (MCS), measuring the emotional domains of QoL (SF, VT, RE, MH) [10].

The extent and type of damage were assessed by the BODI, consisting of 34 items and 12 subitems, categorized into 9 organ/system domains: mucocutaneous, musculoskeletal, ocular, vascular, cardiovascular, neuropsychiatric, gastrointestinal, reproductive system and miscellaneous. Each item and subitem score 1 point, with the total score ranging from 0-46. In the present study, damage accrual was defined as a ∆-BODI ≥1, calculated by subtracting the baseline BODI score from the score recorded at the 2-year follow-up visit. Furthermore, to evaluate the effect of glucocorticoids (GCs) on damage accrual, the individual BODI items were a priori classified into the following categories: definitely related to glucocorticoid (GC) therapy (i.e. diabetes, cataract, osteoporotic fractures or vertebral collapse, avascular necrosis, diabetes), possibly related to GCs (i.e. muscle atrophy, ischaemic heart disease), and independent of GCs (e.g. pulmonary aneurysms, myelopathy), taking into account underlying adverse effects [11, 12].

**Statistical analysis**

Categorical variables were expressed as absolute values and frequencies (%). Normally and nonnormally distributed continuous variables are reported as the mean ± standard deviation (SD) and median and interquartile range (IQR), respectively.

The chi-squared test or Mann–Whitney U-test was used in univariate analysis to identify potential risk factors for damage accrual. Then, a multivariate model for stepwise logistic regression included factors with a p-value < 0.1 in univariate analysis. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Multiple linear regression models were built to assess
the relationship between organ damage accrual and HR-QoL, including the individual and composite SF-36 domains as dependent variables and Δ-BODI ≥ 1 as independent variables. The models included age, sex, disease activity, fibromyalgia, glucocorticoid duration, and major organ involvement as potential confounding factors. The results were reported as a beta (B) coefficient. Statistical significance was set at \( p \)-value < 0.05.

**Results**

Based on the availability and completeness of the follow-up data (Supplementary Fig. 1), out of the 228 patients recruited in the original BODI validation cohort, 189 were enrolled for the analysis of the incidence of damage accrual and associated factors (Table 1), and 147 were enrolled for the assessment of the relationship between damage accrual and HR-QoL (Supplementary Table).

During the 2-year follow-up, the mean (SD) BODI score increased from 1.6 (2.1) to 1.9 (2.1), with a mean (SD) Δ-BODI of 0.3 (0.8) points (\( p < 0.001 \)). Thirty-six (19.0%) patients had an increase ≥1 in the BODI score, with a mean Δ-BODI of 1.7 (0.8) (\( p < 0.001 \)). In addition, the number of patients with at least one item of damage increased from 114 (60.3%) to 131 (69.3%). When the patients were stratified according to disease duration, the incidence of organ damage accrual remained stable, with no significant differences between the different groups (\( p = 0.255 \)), although a trend of a relative increase in the number of patients with at least one GC-related item of damage was recorded (Fig. 1). Overall, 61 new BODI items were recorded, with diabetes (21.3%), mucocutaneous scars (11.5%), visual impairment (11.5%), and osteoporotic fracture or vertebral collapse (8.2%) being the most frequent (Table 2). Twenty-five (41.0%) new BODI items were classified as definitely or possibly related to GC therapy (Fig. 2A). Figure 2B represents the distribution of the new damage items into the different BODI system/organ domains.

**Risk factors of damage accrual over 2 years follow-up**

According to the univariate analysis, factors associated with the accrual of organ damage were older age at enrolment (median 56.2, IQR 42.9–62.0 vs median 46.6, IQR 35.4–53.1 years; \( p = 0.001 \)), more prolonged exposure to GC therapy (median 9.3 years, IQR 2.2–12.3 vs median 2.0 years, IQR 0.7–6.0; \( p < 0.001 \)), and occurrence of at least one relapse (25.0% vs 13.1%; \( p = 0.07 \)). Conversely, patients on treatment with conventional synthetic and biologic immunosuppressants showed a lower likelihood of damage accrual (66.7% vs 86.9%; \( p = 0.004 \)) (Table 3).

| Table 1 Baseline features of the extension BODI cohort (n=189) |
|---------------------------------------------------------------|
| **Demographics**                                             |
| Male gender, n (%)                                            | 92 (48.7) |
| Age at enrolment, mean (SD) years                            | 46.2 (12.1) |
| Age at the disease onset, mean (SD) years                    | 32.6 (11.3) |
| Age at diagnosis, mean (SD) years                            | 35.5 (11.1) |
| Disease duration, mean (SD) years                            | 10.8 (8.3) |
| **Cumulative clinical manifestations**                       |
| Oral aphthosis, n (%)                                        | 186 (98.4) |
| Genital aphthosis, n (%)                                     | 137 (72.5) |
| Skin lesions, n (%)                                          | 137 (72.5) |
| Ocular manifestations, n (%)                                 | 108 (57.1) |
| Neurologic lesions, n (%)                                    | 37 (21.8) |
| Vascular lesions, n (%)                                      | 41 (21.7) |
| Pathergy test, n (%)                                         | 25 (13.2) |
| Arthritis, n (%)                                              | 107 (57.5) |
| Gastrointestinal manifestation, n (%)                        | 27 (14.7) |
| **Active clinical manifestations**                           |
| Oral aphthosis, n (%)                                         | 63 (33.3) |
| Genital aphthosis, n (%)                                      | 12 (6.3) |
| Skin lesions, n (%)                                          | 20 (10.6) |
| Ocular manifestations, n (%)                                 | 12 (6.4) |
| Neurologic lesions, n (%)                                    | 5 (2.7) |
| Vascular lesions, n (%)                                      | 3 (1.6) |
| Arthritis, n (%)                                              | 17 (9.3) |
| Gastrointestinal manifestation, n (%)                        | 9 (5.0) |
| **Ongoing treatment**                                        |
| Glucocorticoid ongoing, n (%)                                | 93 (49.2) |
| Glucocorticoid duration, mean (SD) months                    | 54.9 (66.6) |
| Conventional Immunosuppressantsa, n (%)                      | 81 (42.9) |
| TNF inhibitors, n (%)                                         | 44 (23.3) |
| **Disease activity**                                         |
| BDCAF, mean (SD) score                                       | 2.7 (2.8) |
| PGA, mean (SD) cm                                            | 2.0 (2.1) |
| PtGA, mean (SD) cm                                           | 2.8 (2.6) |
| **Damage**                                                   |
| BODI, mean (SD) score                                        | 1.6 (2.0) |
| BODI ≥ 1, n (%)                                               | 114 (60.3) |

\[\text{BDI = Behçet’s syndrome Overall Damage Index, BDCAF = Behçet’s Disease Current Activity Form, PGA = physician’s global assessment of disease activity, PtGA = patient’s global assessment of disease activity} \]

\* Conventional immunosuppressants: azathioprine, methotrexate, cyclophosphamide, cyclosporine A, sulfasalazine, thalidomide

In the multivariate analysis, the duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07–1.23; \( p < 0.001 \)) and the occurrence of at least one relapse (OR 3.15, 95% CI 1.09–9.12; \( p = 0.038 \)) were confirmed as independent risk factors for damage accrual, whereas the use of conventional or biologic immunosuppressants had an independent protective effect (OR 0.20, 95% CI 0.08–0.54, \( p < 0.001 \)) (Table 3).
In the multiple regression analysis, a significant correlation was recorded between damage accrual and impairment in the PF (B-coefficient $[B] = -13.21$, p-value 0.005) and GH (B $= -11.91$, p $= 0.004$) physical domains of the SF-36 questionnaire. However, the most relevant associations were found between damage accrual and impairment of the RP (B $= -12.39$, p $= 0.018$), VT (B $= -12.13$, p $= 0.006$), SF (B $= -10.59$, p $= 0.035$), RE (B $= -16.51$, p $= 0.001$), and MH (B $= -14.87$, p $< 0.001$) emotional domains of the SF-36 questionnaire, including the MCS (B $= -6.90$, p $= 0.021$) (Table 4, Fig. 3). Female sex, higher disease activity by BDCAF, and fibromyalgia were also independently associated with HR-QoL impairment evaluated by the SF-36 questionnaire (Table 4).

**Discussion**

This study provides original and meaningful data regarding the incidence, type of damage accrual, and associated factors in a multicenter cohort of BS patients prospectively followed up for 2 years. Moreover, the present study demonstrated how organ damage accrual is significantly associated with a decline in HR-QoL, primarily emotional but, to a lesser extent, also physical.

In the BODI cohort, the incidence of damage accrual was remarkable and stable over time, ranging approximately 20% regardless of the disease duration. The stable trend of damage accrual, even in patients with long-standing disease, may seem to be in contrast with the most common type of BS course, in which disease activity and severity tend to abate over time [13]. A partial explanation of this phenomenon may be the prolonged exposure to GC treatment, which was found to be a factor associated with damage accrual independent of other variables, such as disease duration and major organ involvement or the number of immunosuppressants (surrogates of disease severity and resistance to treatment, respectively). Furthermore, when the type of damage was analysed, it
was found that approximately 40% of the newly recorded BODI items were definitely or possibly related to GC treatment, and the percentage of patients with at least one item of GC-related damage increased over time.

Consistent with the described data and the provided interpretation, a longer exposure to GC and an inadequate disease activity control needing an escalation of treatment were identified as independent risk factors for damage accrual. In contrast, the use of immunosuppressants showed a protective effect. The lack of an association between major organ involvement and damage accrual in this study cohort may also be due to the long-standing nature of our BS cohort and the consequent low prevalence of ongoing active visceral involvement. Indeed, the incidence of damage due to disease activity may be significantly higher in the earlier stage of the BS course [14, 15]. Noteworthy, the observed lack of association between damage accrual

---

**Table 3** Uni- and multivariate analysis exploring factors associated with increased risk of damage accrual

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                         | ∆-BODI ≥ 1 (n 36)   | ∆-BODI = 0 (n 153)   | p          | OR (95%CI) | p            |
| Male gender              | 16 (44.4%)          | 76 (49.7%)            | 0.572     | ---       | ---          |
| Age at enrolment         | 56.2 (42.9–62.0)    | 46.6 (35.4–53.1)      | **0.001** | ---       | ---          |
| Disease duration         | 12.9 (7.1–17.5)     | 11.1 (5.4–21.2)       | 0.483     | ---       | ---          |
| Major organ involvementa| 22 (61.1%)          | 72 (47.1%)            | 0.129     | ---       | ---          |
| BDCAF at baseline        | 3 (0–5)             | 2 (0–5)               | 0.365     | ---       | ---          |
| BDCAF at follow-up visit | 3 (3–5)             | 3 (0–7)               | 0.188     | ---       | ---          |
| Glucocorticoid duration  | 9.3 (2.2–12.3)      | 2.0 (0.7–6.0)         | **<0.001** | 1.150 (1.072–1.234) | **<0.001** |
| Immunosuppressantb       | 24 (66.7%)          | 133 (86.9%)           | **0.004** | 0.201 (0.076–0.536) | **<0.001** |
| Cumulative n of immunosuppressants | 2 (1–2) | 2 (1–3) | 0.162 |
| At least 1 relapse       | 9 (25.0%)           | 20 (13.1%)            | **0.070** | 3.146 (1.085–9.120) | **0.038** |
| BODI score at baseline   | 1.0 (0–2.0)         | 1 (0–2)               | 0.579     | ---       | ---          |

In the univariate analysis, continuous variables are expressed as median (IQR) and categorical variables as number (%). Interval—age, disease duration and glucocorticoids refer to years. BODI, Behçet’s Syndrome Overall Damage Index; BDCAF, Behçet’s Disease Current Activity Form; OR, odds ratio

a Cumulative vascular, neurologic, gastrointestinal manifestations

b Conventional and biologic immunosuppressants: azathioprine, methotrexate, cyclophosphamide, cyclosporine A, sulfasalazine, thalidomide, TNF-alpha inhibitors
and the BDCAF, measured at the baseline and follow-up visit, does not mean that disease activity is not a determinant of damage. This is because the damage is also strongly related to the duration of disease activity. Thus, the assessment of disease activity at single time points may prevent capturing its association with damage accrual.

Finally, this study provides the first evidence regarding the influence of damage accrual on the impairment of HR-QoL, which is included in the outcomes core set for the monitoring and management of BS [16]. In the cross-sectional phase of the BODI validation study, no correlation between the extent of damage expressed as the total BODI score and the concomitant mental and physical domains of the SF-36 was found [3]. However, we speculated that this lack of association might be due to coping mechanisms, as observed in other chronic diseases [17, 18]. Following this assumption, in the present longitudinal

Table 4 Results of multiple linear regression (B coefficients) exploring factors independently associated with HR-QoL

| SF-36 Domains | PF | RP | BP | GH | VT | SF | RE | MH | PCS | MCS |
|---------------|----|----|----|----|----|----|----|----|-----|-----|
| $\Delta$-BODI $\geq 1$ | $-13.21^b$ | $-12.39^f$ | $-$ | $-11.91^b$ | $-12.13^b$ | $-10.59^f$ | $-16.51^b$ | $-14.87^f$ | $-$ | $-6.90^i$ |
| Female | $-10.76^b$ | $-15.86^d$ | $-19.58^d$ | $-10.55^b$ | $-14.77^f$ | $-17.47^d$ | $-13.33^d$ | $-$ | $-6.42^f$ | $-4.24^d$ |
| Fibromyalgia | $-30.07^g$ | $-33.27^g$ | $-26.19^g$ | $-24.24^g$ | $-22.29^d$ | $-27.48^d$ | $-20.56^i$ | $-25.31^f$ | $-10.56^g$ | $-9.49^g$ |
| BDCAF | $-1.25^i$ | $-2.11^i$ | $-2.493^d$ | $-2.89^d$ | $-2.91^c$ | $-1.60^c$ | $-1.83^b$ | $-1.91^d$ | $-0.77^d$ | $-0.95^d$ |
| Age | $-0.51^c$ | $-$ | $-0.58^d$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ |
| GC duration | $-$ | $-$ | $-0.140^d$ | $-$ | $-$ | $-$ | $-$ | $-0.09^i$ | $-$ | $-$ |
| Major organ involvement | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ |
| Immunosuppressants | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ | $-$ |

HR-QoL, health-related quality of life, SF-36 Short form 36 questionnaire for assessment of HR-QoL, PF physical functioning, RP role physical, BP bodily pain, GH general health, MH mental health, VT vitality, SF social functioning, RE role emotional, MCS mental component summary, PCS physical component summary, GC glucocorticoids

* Conventional and biologic immunosuppressants: azathioprine, methotrexate, cyclophosphamide, cyclosporine A, sulfasalazine, thalidomide, TNF-alpha inhibitors

† $p < 0.05$, § $p < 0.01$, # $p < 0.001$ in multiple regression

Fig. 3 Radar plot representing the mean values of each SF-36 domain in patients having ($\Delta$-BODI $\geq 1$) or not ($\Delta$-BODI=0) accrual of organ damage over the 2 years of follow-up. PF, physical function; RP, role-physical; BP, body pain; GH, general health; VT, vitality; SF, social function; RE, role emotional; MH, mental health. * $p < 0.05$, § $p < 0.01$, # $p < 0.001$ in multiple regression
extension of the BODI project, we found that the accrual of organ damage, rather than its extent assessed in a single visit, was associated with impairment of different aspects of HR-QoL, especially those mental related.

This study has several strengths. It first addressed the topic of damage accrual in BS as a prospective analysis and simultaneously analysed its determinant and outcomes, assuring higher completeness and consistency of the provided model. In addition, the risk factors and damage outcomes analysis was adjusted for major confounding covariates and provided coherent results with a fully rational explanation. Finally, this study provides data in support of the criterion validity of the BODI. Indeed, although a standardized and validated definition of a minimally important change in the BODI score is not currently available, this study showed that an increase of ≥1 has a relevant impact on patient quality of life.

Some limitations are also present in this study. The long-standing nature of the studied cohort and the relatively low proportion of patients with “major organ involvement” (which may be considered a surrogate of disease severity) may prevent a complete and time-related description of the trajectory of organ damage accrual. In addition, the definition of relapses as an increase in treatment due to disease activity is not validated in BS, although it may be considered a valid surrogate. Finally, further validation of the BODI in wider and ethnically heterogeneous cohorts, unrelated to the original BODI cohort, with earlier disease and longer follow-up duration is needed.

In conclusion, this study highlights how measuring and targeting organ damage is crucial in the management of BS to prevent its progressive accrual and the related impairment of perceived physical and mental health. This is especially relevant considering the need to design strategies for patient empowerment and self-management [19]. From this perspective, the use of an adequate immunosuppressive therapy, minimizing steroid exposure, and lowering the risk of relapse seem to have a key role in preventing damage accrual. However, further research in larger inception cohorts of BS patients followed for a longer time is needed to validate these results.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02947-y.

Acknowledgements

The authors thank all the patients participating in this research and the Italian Behçet’s Syndrome Patient Association (SIMBA ODV) for supporting and disseminating this initiative.

Authors’ contributions

Study conception: AF, AM, AC, MP. Study design: AF, MG, LC, GB, JC, FI, RC, AM, CV, AC, MP. Acquisition, analysis or interpretation of the data: AF, RL, GE, GL, LSP, NK, JS, ALM, MG, LC, GB, JC, FI, RC, CV, AM, AC, MP. Drafting the article or substantively revised it: AF, RL, GE, GL, LSP, NK, JS, ALM, MG, LC, GB, JC, FI, RC, CV, AM, AC, MP. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the coordinating centre at the AOU of Cagliari (Prot. PG/2018/17158, last version, 3rd of September 2020). All participants gave their written informed consent.

Consent for publication

Consent for publication was obtained.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Medical Sciences and Public Health, University of Cagliari, SS 554, 09042 Monserrato, CA, Italy. 2Rheumatology Unit, Azienda Ospedaliero-Universitaria di Cagliari, Monserrato, Italy. 3Department of Autoimmune Diseases, University of Barcelona, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. 4University of Bari, Rheumatology Unit, Bari, Italy. 5Hospital Santo Antonio Centro Hospitalar do Porto, Unidade de Imunologia Clínica, Porto, Portugal. 6Rheumatology, Clinical Immunology and Allergy Unit, University of Cetra, Heraklion, Greece. 7Fourth Department of Internal Medicine, School of Medicine, Hippokration Hospital, Thessaloniki, Greece. 8Rheumatology Unit, University of Siena, Siena, Italy. 9Rheumatology Unit - AOU, S. Anna, Ferrara, University of Ferrara, Ferrara, Italy. 10University of Porto, UIMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal.

Received: 15 June 2022   Accepted: 3 November 2022

Published online: 17 November 2022

References

1. Piga M, Mathieu A. Genetic susceptibility to Behçet’s disease: role of genes belonging to the MHC region. Rheumatol (Oxford). 2011;50:299–310.
2. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.
3. Piga M, Floris A, Espinosa G, Pinto LS, Kouktsas N, Monaco AL, et al. Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI). RMD Open. 2020;6:e001192.
4. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77:808–18.
5. Antay-Bedregal D, Camargo-Revello E, Alvarado GF. Associated factors vs risk factors in cross-sectional studies. Patient Prefer Adherence. 2015;9:1635–6.
6. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet Lond Engl. 1990;335:1078–80.
7. Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.
8. Bhakta BB, Brennan P, James TE, Chamberlain MA, Nobile BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728–33.
9. Floris A, Espinosa G, Serpa Pinto L, Kougkas N, Lo Monaco A, Lopalco G, et al. Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort. Arthritis Res Ther. 2020;22:278.
10. Ertam I, Kitapcioglu G, Aksu K, Keser G, Ozaksar A, Elbi H, et al. Quality of life and its relation with disease severity in Behçet’s disease. Clin Exp Rheumatol. 2009;27(2 Suppl 53):S18–22.
11. Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16:133–44.
12. Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Bultegeit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905–13.
13. Kural-Seyahi E, Fresko I, Seyahi N, Ozuyozgan Y, Mat C, Hamuryudan V, et al. The Long-Term Mortality and Morbidity of Behçet Syndrome: A 2-Decade Outcome Survey of 387 Patients Followed at a Dedicated Center. Medicine (Baltimore). 2003;82:60.
14. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177–84.
15. Wawrzyncka-Adamczyk K, Floris A, Robson J, Szajd J, Craven A, Watts RA, et al. 284 Differences in Early Damage Patterns in Various Forms of Primary Systemic Vasculitis. Rheumatology. 2016;55:i77.
16. Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Shea B, et al. The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. Arthritis Care Res. 2022;74(4):691–9.
17. Legge A, Doucette S, Hanly JG. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2016;43:1050–6.
18. Faurschou M, Sigaard L, Bjorner JB, Baslund B. Impaired Health-related Quality of Life in Patients Treated for Wegener’s Granulomatosis. J Rheumatol. 2010;37:2081–5.
19. Mannello D, Di Cianni F, Del Bianco A, Mattioli I, Sota J, Cantarini L, et al. Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet’s Syndrome. Front Med (Lausanne). 2021;8:769870.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.